NO20024643D0 - Fremgangsmåte for forbedring av öy-signalisering i diabetes mellitus og for forebygging derav - Google Patents

Fremgangsmåte for forbedring av öy-signalisering i diabetes mellitus og for forebygging derav

Info

Publication number: NO20024643D0
Authority: NO; Norway
Prior art keywords: cells; insulin producing; pancreatic; glp; preventing
Prior art date: 2000-03-31

Application number

NO20024643A

Other languages

English (en)

Other versions

NO20024643L (no

Inventor

Hans-Ulrich Demuth

Konrad Glund

Original Assignee

Probiodrug Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-03-31

Filing date

2002-09-27

Publication date

2002-09-27

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22716142&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20024643(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-09-27 Application filed by Probiodrug Ag filed Critical Probiodrug Ag

2002-09-27 Publication of NO20024643D0 publication Critical patent/NO20024643D0/no

2002-11-05 Publication of NO20024643L publication Critical patent/NO20024643L/no

Links

238000000034 method Methods 0.000 title abstract 2
206010012601 diabetes mellitus Diseases 0.000 title 1
230000011664 signaling Effects 0.000 title 1
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 6
102000004877 Insulin Human genes 0.000 abstract 3
108090001061 Insulin Proteins 0.000 abstract 3
229940125396 insulin Drugs 0.000 abstract 3
102100025101 GATA-type zinc finger protein 1 Human genes 0.000 abstract 2
101710198884 GATA-type zinc finger protein 1 Proteins 0.000 abstract 2
DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 abstract 2
230000004069 differentiation Effects 0.000 abstract 2
241000124008 Mammalia Species 0.000 abstract 1
210000004027 cell Anatomy 0.000 abstract 1
210000002919 epithelial cell Anatomy 0.000 abstract 1
230000002641 glycemic effect Effects 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
238000012423 maintenance Methods 0.000 abstract 1
210000004923 pancreatic tissue Anatomy 0.000 abstract 1
230000004962 physiological condition Effects 0.000 abstract 1
230000008929 regeneration Effects 0.000 abstract 1
238000011069 regeneration method Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Immunology (AREA)
Endocrinology (AREA)
Communicable Diseases (AREA)
Physical Education & Sports Medicine (AREA)
Oncology (AREA)
Rheumatology (AREA)
Obesity (AREA)
Virology (AREA)
Hematology (AREA)
Transplantation (AREA)
Emergency Medicine (AREA)
Pain & Pain Management (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Orthopedic Medicine & Surgery (AREA)
Molecular Biology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Enzymes And Modification Thereof (AREA)
Thiazole And Isothizaole Compounds (AREA)

NO20024643A 2000-03-31 2002-09-27 FremgangsmÕte for forbedring av öy-signalisering i diabetes mellitus og for forebygging derav NO20024643L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US19406100P	2000-03-31	2000-03-31
PCT/EP2001/003725 WO2001072290A2 (en)	2000-03-31	2001-04-02	Method for the improvement of islet signaling in diabetes mellitus and for its prevention

Publications (2)

Publication Number	Publication Date
NO20024643D0 true NO20024643D0 (no)	2002-09-27
NO20024643L NO20024643L (no)	2002-11-05

Family

ID=22716142

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20024643A NO20024643L (no)	2000-03-31	2002-09-27	FremgangsmÕte for forbedring av öy-signalisering i diabetes mellitus og for forebygging derav

Country Status (21)

Country	Link
US (5)	US6500804B2 (no)
EP (3)	EP2055302B1 (no)
JP (1)	JP2003528135A (no)
KR (2)	KR20030019337A (no)
CN (2)	CN1420797A (no)
AT (1)	ATE419036T1 (no)
AU (2)	AU2001254763A1 (no)
BR (1)	BR0109553A (no)
CA (1)	CA2400226C (no)
CY (1)	CY1108872T1 (no)
CZ (1)	CZ20023234A3 (no)
DE (1)	DE60137216D1 (no)
DK (2)	DK1283735T4 (no)
ES (3)	ES2525041T3 (no)
HU (1)	HU229042B1 (no)
IL (1)	IL151368A0 (no)
NO (1)	NO20024643L (no)
PT (3)	PT1283735E (no)
RU (1)	RU2261096C2 (no)
WO (1)	WO2001072290A2 (no)
ZA (1)	ZA200206460B (no)

Families Citing this family (122)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20020006899A1 (en) *	1998-10-06	2002-01-17	Pospisilik Andrew J.	Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals
CN1163594C (zh)	1997-09-29	2004-08-25	尖端医疗有限公司	体外造血细胞的刺激
DE19823831A1 (de) *	1998-05-28	1999-12-02	Probiodrug Ges Fuer Arzneim	Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
DE19828113A1 (de) *	1998-06-24	2000-01-05	Probiodrug Ges Fuer Arzneim	Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
US6979697B1 (en) *	1998-08-21	2005-12-27	Point Therapeutics, Inc.	Regulation of substrate activity
US20030176357A1 (en) *	1998-10-06	2003-09-18	Pospisilik Andrew J.	Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels
US6890904B1 (en) *	1999-05-25	2005-05-10	Point Therapeutics, Inc.	Anti-tumor agents
DE19940130A1 (de) *	1999-08-24	2001-03-01	Probiodrug Ges Fuer Arzneim	Neue Effektoren der Dipeptidyl Peptidase IV zur topischen Anwendung
US20030040469A1 (en) *	2000-03-08	2003-02-27	Knudsen Liselotte Bjerre	Lowering serum lipids
ES2525041T3 (es) *	2000-03-31	2014-12-16	Royalty Pharma Collection Trust	Método para la mejora de la señalización de islotes en diabetes mellitus y para su prevención
IL155157A0 (en) *	2000-10-27	2003-10-31	Probiodrug Ag	Pharmaceutical compositions containing an attractin inhibitor
US20020187926A1 (en) *	2001-03-07	2002-12-12	Knudsen Liselotte Bjerre	Combined use of derivatives of GLP-1 analogs and PPAR ligands
US20030022816A1 (en) *	2001-03-07	2003-01-30	Knudsen Liselotte Bjerre	Combined use of derivatives of GLP-1 analogs and PPAR ligands
US20070293426A1 (en) *	2001-04-02	2007-12-20	Hans-Ulrich Demuth	Methods for improving islet signaling in diabetes mellitus and for its prevention
US6890905B2 (en) *	2001-04-02	2005-05-10	Prosidion Limited	Methods for improving islet signaling in diabetes mellitus and for its prevention
GB0109146D0 (en) *	2001-04-11	2001-05-30	Ferring Bv	Treatment of type 2 diabetes
US20030130199A1 (en) *	2001-06-27	2003-07-10	Von Hoersten Stephan	Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents
ATE374181T1 (de)	2001-06-27	2007-10-15	Smithkline Beecham Corp	Fluorpyrrolidine als dipeptidylpeptidaseinhibitoren
US7368421B2 (en) *	2001-06-27	2008-05-06	Probiodrug Ag	Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis
US20040214762A1 (en) *	2001-08-16	2004-10-28	Hans-Ulrich Demuth	Use of inhibitors of proline endopeptidase to modulate inositol (1,4,5) triphosphate concentration dependent on intracellular signal cascades
US6844316B2 (en) *	2001-09-06	2005-01-18	Probiodrug Ag	Inhibitors of dipeptidyl peptidase I
WO2003045228A2 (en) *	2001-11-26	2003-06-05	Trustees Of Tufts College	Methods for treating autoimmune disorders, and reagents related thereto
NZ534877A (en) *	2002-02-28	2006-05-26	Prosidion Ltd	Glutaminyl based DPIV inhibitors
US20030232761A1 (en) *	2002-03-28	2003-12-18	Hinke Simon A.	Novel analogues of glucose-dependent insulinotropic polypeptide
JP2005533775A (ja)	2002-06-07	2005-11-10	ワラタファーマシューティカルズ，インコーポレイテッド	糖尿病を処置するための組成物および方法
ES2306781T3 (es) *	2002-08-09	2008-11-16	Prosidion Ltd.	Inhibidores de la dipeptidil-peptidasa iv para disminucion de la tasa de aumento cronico de peso.
US7407955B2 (en)	2002-08-21	2008-08-05	Boehringer Ingelheim Pharma Gmbh & Co., Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
EP1537880A4 (en) *	2002-09-11	2009-07-01	Takeda Pharmaceutical	Sustained release preparation
EP1543023B1 (en) *	2002-09-18	2010-03-17	Prosidion Limited	Secondary binding site of dipeptidyl peptidase iv (dp iv)
US20040058876A1 (en) *	2002-09-18	2004-03-25	Torsten Hoffmann	Secondary binding site of dipeptidyl peptidase IV (DP IV)
BR0315523A (pt) *	2002-10-22	2005-08-30	Waratah Pharmaceuticals Inc	Tratamento de diabetes
DE10308351A1 (de)	2003-02-27	2004-11-25	Aventis Pharma Deutschland Gmbh	1,3-substituierte Cycloalkylderivate mit sauren, meist heterocyclischen Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE10308353A1 (de)	2003-02-27	2004-12-02	Aventis Pharma Deutschland Gmbh	Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE10308352A1 (de)	2003-02-27	2004-09-09	Aventis Pharma Deutschland Gmbh	Arylcycloalkylderivate mit verzweigten Seitenketten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
US7148246B2 (en)	2003-02-27	2006-12-12	Sanofi-Aventis Deutschland Gmbh	Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals
DE10308355A1 (de)	2003-02-27	2004-12-23	Aventis Pharma Deutschland Gmbh	Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
US20040242566A1 (en) *	2003-03-25	2004-12-02	Syrrx, Inc.	Dipeptidyl peptidase inhibitors
US7371871B2 (en) *	2003-05-05	2008-05-13	Probiodrug Ag	Inhibitors of glutaminyl cyclase
KR20110059664A (ko) *	2003-05-05	2011-06-02	프로비오드룩 아게	글루타미닐 및 글루타메이트 사이클라제의 이펙터의 용도
EP1625122A1 (en)	2003-05-14	2006-02-15	Takeda San Diego, Inc.	Dipeptidyl peptidase inhibitors
CA2535619A1 (en)	2003-08-13	2005-02-24	Takeda Pharmaceutical Company Limited	4-pyrimidone derivatives and their use as peptidyl peptidase inhibitors
US7678909B1 (en)	2003-08-13	2010-03-16	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
US7169926B1 (en)	2003-08-13	2007-01-30	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
EP1697342A2 (en) *	2003-09-08	2006-09-06	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
JP2007505121A (ja)	2003-09-08	2007-03-08	武田薬品工業株式会社	ジペプチジルぺプチダーゼ阻害剤
CN1867324A (zh) *	2003-10-15	2006-11-22	前体生物药物股份公司	谷氨酰胺酰基环化酶效应物和谷氨酸环化酶效应物的应用
ES2231036B1 (es) *	2003-10-31	2006-07-01	Encofrados J. Alsina, S.A.	Puntal.
US20100099721A1 (en) *	2003-11-03	2010-04-22	Probiodrug Ag	Novel compounds for the treatment of neurological disorders
US20050171112A1 (en) *	2003-11-03	2005-08-04	Probiodrug Ag	Combinations useful for the treatment of neuronal disorders
KR20130105741A (ko)	2003-11-17	2013-09-25	노파르티스 아게	디펩티딜 펩티다제 ⅳ 억제제의 용도
BR122018014389B1 (pt)	2004-01-20	2023-04-25	Novartis Ag	Processo para preparar comprimido farmacêutico por compressão direta
US7241787B2 (en) *	2004-01-25	2007-07-10	Sanofi-Aventis Deutschland Gmbh	Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments
BRPI0507485A (pt)	2004-02-05	2007-07-10	Probiodrug Ag	inibidores novos de glutaminil ciclase
US7501426B2 (en)	2004-02-18	2009-03-10	Boehringer Ingelheim International Gmbh	8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
RU2379315C2 (ru) *	2004-02-23	2010-01-20	Трастиз Оф Тафтс Колледж	Ингибиторы дипептидилпептидазы iv
US7732446B1 (en)	2004-03-11	2010-06-08	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
GEP20094679B (en)	2004-03-15	2009-05-10	Takeda Pharmaceuticals Co	Dipeptidyl peptidase inhibitors
EP1586573B1 (en)	2004-04-01	2007-02-07	Sanofi-Aventis Deutschland GmbH	Oxadiazolones, processes for their preparation and their use as pharmaceuticals
US7687638B2 (en)	2004-06-04	2010-03-30	Takeda San Diego, Inc.	Dipeptidyl peptidase inhibitors
WO2006019965A2 (en)	2004-07-16	2006-02-23	Takeda San Diego, Inc.	Dipeptidyl peptidase inhibitors
CN101087756B (zh)	2004-07-23	2011-04-06	纽阿达有限责任公司	肽酶抑制剂
US20070259927A1 (en) *	2004-08-26	2007-11-08	Takeda Pharmaceutical Company Limited	Remedy for Diabetes
US20060063719A1 (en) *	2004-09-21	2006-03-23	Point Therapeutics, Inc.	Methods for treating diabetes
DE102004054054A1 (de)	2004-11-05	2006-05-11	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
US7872124B2 (en)	2004-12-21	2011-01-18	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
ES2477868T3 (es) *	2005-04-22	2014-07-18	Alantos Pharmaceuticals Holding, Inc.	Inhibidores de dipeptidil peptidasa-IV
DE102005026762A1 (de)	2005-06-09	2006-12-21	Sanofi-Aventis Deutschland Gmbh	Azolopyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholipasen
MY152185A (en)	2005-06-10	2014-08-29	Novartis Ag	Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
DE102005035891A1 (de)	2005-07-30	2007-02-08	Boehringer Ingelheim Pharma Gmbh & Co. Kg	8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
WO2007024899A2 (en) *	2005-08-23	2007-03-01	The General Hospital Corporation	Use of glp-1, glp-1 derivatives or glp-1 fragments for skin regeneration, stimulation of hair growth, or treatment of diabetes
ME02005B (me)	2005-09-14	2012-08-31	Takeda Pharmaceuticals Co	Inhibitori dipeptidil peptidaze za lečenje dijabetesa
PE20070622A1 (es) *	2005-09-14	2007-08-22	Takeda Pharmaceutical	Administracion de inhibidores de dipeptidil peptidasa
CN101309689B (zh) *	2005-09-14	2012-10-10	武田药品工业株式会社	用于治疗糖尿病的二肽基肽酶抑制剂
TW200745080A (en) *	2005-09-16	2007-12-16	Takeda Pharmaceuticals Co	Polymorphs of tartrate salt of 2-[2-(3-(R)-amino-piperidin-1-yl)-5-fluoro-6-oxo-6H-pyrimidin-1-ylmethyl]-benzonitrile and methods of use therefor
TW200745079A (en) *	2005-09-16	2007-12-16	Takeda Pharmaceuticals Co	Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor
CN101360723A (zh)	2005-09-16	2009-02-04	武田药品工业株式会社	制备嘧啶二酮衍生物的方法
CN101272780A (zh) *	2005-09-30	2008-09-24	诺瓦提斯公司	用于自身免疫疾病和移植排斥治疗的dpp iv抑制剂
CA2625150A1 (en) *	2005-10-07	2007-04-19	Waratah Pharmaceuticals, Inc.	Combined use of dpp-iv inhibitors and gastrin compounds
AT502717A1 (de) *	2005-11-09	2007-05-15	Omnica Gmbh	Pharmazeutische verwendung einer verbindung
GB0526291D0 (en)	2005-12-23	2006-02-01	Prosidion Ltd	Therapeutic method
WO2007112347A1 (en)	2006-03-28	2007-10-04	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
JP2009531456A (ja) *	2006-03-28	2009-09-03	武田薬品工業株式会社	（ｒ）−３−アミノピペリジン二塩酸塩の調製
EP1852108A1 (en)	2006-05-04	2007-11-07	Boehringer Ingelheim Pharma GmbH & Co.KG	DPP IV inhibitor formulations
KR101452915B1 (ko)	2006-05-04	2014-10-21	베링거 인겔하임 인터내셔날 게엠베하	다형태
PE20080251A1 (es)	2006-05-04	2008-04-25	Boehringer Ingelheim Int	Usos de inhibidores de dpp iv
DK2073810T3 (da) *	2006-09-13	2011-10-31	Takeda Pharmaceutical	Anvendelse af 2-6-(3-aminio-piperidin-l-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-l-ylmethyl-4-fluor-benzonitril til behandling af diabetes, cancer, autoimmune sygdomme og HIV infektion
US8324383B2 (en)	2006-09-13	2012-12-04	Takeda Pharmaceutical Company Limited	Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
TW200838536A (en)	2006-11-29	2008-10-01	Takeda Pharmaceutical	Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en)	2007-03-13	2012-01-10	Takeda Pharmaceuticals Company Limited	Weekly administration of dipeptidyl peptidase inhibitors
US20080293644A1 (en) *	2007-04-27	2008-11-27	Thomas Eidenberger	Guava extract
NZ600126A (en) *	2007-08-17	2013-12-20	Boehringer Ingelheim Int	Purine derivatives for use in the treatment of fap-related diseases
PE20140960A1 (es)	2008-04-03	2014-08-15	Boehringer Ingelheim Int	Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) *	2008-06-03	2010-02-23	Boehringer Ingelheim Int	Tratamiento de nafld
KR20190016601A (ko)	2008-08-06	2019-02-18	베링거 인겔하임 인터내셔날 게엠베하	메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es)	2008-08-06	2010-03-26	Boehringer Ingelheim Int	"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
WO2010018217A2 (en) *	2008-08-15	2010-02-18	Boehringer Ingelheim International Gmbh	Organic compounds for wound healing
MX2011002558A (es)	2008-09-10	2011-04-26	Boehringer Ingelheim Int	Terapia de combinacion para el tratamiento de diabetes y estados relacionados.
US20200155558A1 (en)	2018-11-20	2020-05-21	Boehringer Ingelheim International Gmbh	Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
US9144205B2 (en)	2008-10-17	2015-09-29	Alchem Environmental Ip Llc	Hydroponics applications and ancillary modifications to a polyphasic pressurized homogenizer
US8241410B1 (en)	2008-10-17	2012-08-14	Alchem Environmental LLC	Ancillary embodiments and modifications to a polyphasic pressurized homogenizer
US9757683B1 (en)	2008-10-17	2017-09-12	Alchem Environmental Ip Llc	Polyphasic pressurized homogenizer (PPH) and methods for methane purification
AU2009331471B2 (en)	2008-12-23	2015-09-03	Boehringer Ingelheim International Gmbh	Salt forms of organic compound
AR074990A1 (es)	2009-01-07	2011-03-02	Boehringer Ingelheim Int	Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
US9655003B2 (en) *	2009-03-19	2017-05-16	Georgia Tech Research Corporation	Systems and methods for improved wireless interface aggregation
KR20120107080A (ko)	2009-11-27	2012-09-28	베링거 인겔하임 인터내셔날 게엠베하	리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
KR101927068B1 (ko)	2010-05-05	2018-12-10	베링거 인겔하임 인터내셔날 게엠베하	체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법
KR20220025926A (ko)	2010-06-24	2022-03-03	베링거 인겔하임 인터내셔날 게엠베하	당뇨병 요법
AR083878A1 (es)	2010-11-15	2013-03-27	Boehringer Ingelheim Int	Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
CN102807568B (zh) *	2011-05-31	2015-11-25	正大天晴药业集团股份有限公司	噻二唑衍生物类dpp-iv抑制剂
CN103781788B (zh)	2011-07-15	2016-08-17	勃林格殷格翰国际有限公司	经取代的喹唑啉、其制备及其在药物组合物中的用途
US9555001B2 (en)	2012-03-07	2017-01-31	Boehringer Ingelheim International Gmbh	Pharmaceutical composition and uses thereof
JP6224084B2 (ja)	2012-05-14	2017-11-01	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
WO2013171166A1 (en)	2012-05-14	2013-11-21	Boehringer Ingelheim International Gmbh	A xanthine derivative as dpp-4 inhibitor for use in the treatment of sirs and/or sepsis
WO2013174767A1 (en)	2012-05-24	2013-11-28	Boehringer Ingelheim International Gmbh	A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
JP6615109B2 (ja)	2014-02-28	2019-12-04	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｄｐｐ−４阻害薬の医学的使用
CN105315301B (zh) *	2014-08-05	2018-04-03	连云港润众制药有限公司	噻二唑类dpp‑ⅳ抑制剂的枸橼酸盐
EP3267994A4 (en)	2015-03-09	2018-10-31	Intekrin Therapeutics, Inc.	Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
MX390363B (es)	2016-06-10	2025-03-20	Boehringer Ingelheim Int	Combinacion de linagliptina y metformina
CN106620704A (zh) *	2016-11-04	2017-05-10	广州赛莱拉干细胞科技股份有限公司	一种治疗糖尿病的制剂及其制备方法和应用
WO2018162722A1 (en)	2017-03-09	2018-09-13	Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke	Dpp-4 inhibitors for use in treating bone fractures
SG11201909046XA (en)	2017-04-03	2019-10-30	Coherus Biosciences Inc	PPARγ AGONIST FOR TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY
CN112386217A (zh) *	2019-08-14	2021-02-23	关永晖	一种膀胱镜注射针

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2961377A (en)	1957-08-05	1960-11-22	Us Vitamin Pharm Corp	Oral anti-diabetic compositions and methods
US3174901A (en) *	1963-01-31	1965-03-23	Jan Marcel Didier Aron Samuel	Process for the oral treatment of diabetes
DE2009743A1 (de)	1970-03-03	1971-09-16	Farbenfabriken Bayer Ag, 5090 Leverkusen	Substituierte Biguanide mit antihyperglykämischer Wirkung
US3879541A (en) *	1970-03-03	1975-04-22	Bayer Ag	Antihyperglycemic methods and compositions
US3960949A (en)	1971-04-02	1976-06-01	Schering Aktiengesellschaft	1,2-Biguanides
CH602612A5 (no)	1974-10-11	1978-07-31	Hoffmann La Roche
US4935493A (en)	1987-10-06	1990-06-19	E. I. Du Pont De Nemours And Company	Protease inhibitors
US5433955A (en)	1989-01-23	1995-07-18	Akzo N.V.	Site specific in vivo activation of therapeutic drugs
US5462928A (en) *	1990-04-14	1995-10-31	New England Medical Center Hospitals, Inc.	Inhibitors of dipeptidyl-aminopeptidase type IV
JPH04334357A (ja)	1991-05-02	1992-11-20	Fujirebio Inc	酵素阻害作用を有するアシル誘導体
CA2121369C (en)	1991-10-22	2003-04-29	William W. Bachovchin	Inhibitors of dipeptidyl-aminopeptidase type iv
DK36392D0 (da) *	1992-03-19	1992-03-19	Novo Nordisk As	Anvendelse af kemisk forbindelse
IL106998A0 (en)	1992-09-17	1993-12-28	Univ Florida	Brain-enhanced delivery of neuroactive peptides by sequential metabolism
FR2696740B1 (fr)	1992-10-13	1994-12-30	Dospharma Sa	Dérivés prodrogués de la diméthylbiguanide et applications comme médicaments.
WO1995011689A1 (en)	1993-10-29	1995-05-04	Trustees Of Tufts College	Use of inhibitors of dipeptidyl-aminopeptidase to block entry of hiv into cells
IL111785A0 (en) *	1993-12-03	1995-01-24	Ferring Bv	Dp-iv inhibitors and pharmaceutical compositions containing them
US5705483A (en) *	1993-12-09	1998-01-06	Eli Lilly And Company	Glucagon-like insulinotropic peptides, compositions and methods
US5543396A (en)	1994-04-28	1996-08-06	Georgia Tech Research Corp.	Proline phosphonate derivatives
US5512549A (en)	1994-10-18	1996-04-30	Eli Lilly And Company	Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5614379A (en)	1995-04-26	1997-03-25	Eli Lilly And Company	Process for preparing anti-obesity protein
DE122010000020I1 (de) *	1996-04-25	2010-07-08	Prosidion Ltd	Verfahren zur Senkung des Blutglukosespiegels in Säugern
CA2256669A1 (en)	1996-05-29	1997-12-04	Prototek, Inc.	Prodrugs of thalidomide and methods for using same as modulators of t-cell function
US6006753A (en)	1996-08-30	1999-12-28	Eli Lilly And Company	Use of GLP-1 or analogs to abolish catabolic changes after surgery
US5827898A (en) *	1996-10-07	1998-10-27	Shaman Pharmaceuticals, Inc.	Use of bisphenolic compounds to treat type II diabetes
US6011155A (en) *	1996-11-07	2000-01-04	Novartis Ag	N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
TW492957B (en)	1996-11-07	2002-07-01	Novartis Ag	N-substituted 2-cyanopyrrolidnes
AR016751A1 (es)	1996-11-22	2001-08-01	Athena Neurosciences Inc	Metodo para inhibir la liberacion del peptido beta-amiloide en una celula, composicion farmaceutica y compuestos utiles en dicho metodo
US6001155A (en)	1997-03-17	1999-12-14	Pease; John R.	Polyphasic pressurized homogenizer
CA2819705C (en)	1998-02-02	2014-07-08	Trustees Of Tufts College	Method of regulating glucose metabolism, and reagents related thereto
JP2002506075A (ja)	1998-03-09	2002-02-26	フォンダテッヒ・ベネルクス・ナムローゼ・フェンノートシャップ	セリンペプチダーゼ調節剤
DE19823831A1 (de) †	1998-05-28	1999-12-02	Probiodrug Ges Fuer Arzneim	Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
DE19828113A1 (de)	1998-06-24	2000-01-05	Probiodrug Ges Fuer Arzneim	Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
DE19828114A1 (de)	1998-06-24	2000-01-27	Probiodrug Ges Fuer Arzneim	Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
EP1092046A4 (en)	1998-07-02	2003-02-19	Invitro Diagnostics Inc	METHODS, COMPOSITIONS AND DEVICE FOR MANUFACTURING NUCLEIC ACIDS HAVING SELECTIVE AFFINITY FOR A TARGET MOLECULE
DE69911975T2 (de)	1998-07-31	2004-09-09	Novo Nordisk A/S	In-vitro stimulation von beta zellen vermehrung
DE19834591A1 (de)	1998-07-31	2000-02-03	Probiodrug Ges Fuer Arzneim	Verfahren zur Steigerung des Blutglukosespiegels in Säugern
AU3960400A (en)	1999-03-05	2000-09-28	Molteni L. E C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A.	Use of metformin in the preparation of pharmaceutical compositions capable of inhibiting the enzyme dipeptidyl peptidase iv
US6107317A (en) *	1999-06-24	2000-08-22	Novartis Ag	N-(substituted glycyl)-thiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
US6110949A (en) *	1999-06-24	2000-08-29	Novartis Ag	N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
US6172081B1 (en) *	1999-06-24	2001-01-09	Novartis Ag	Tetrahydroisoquinoline 3-carboxamide derivatives
US7064145B2 (en) *	2000-02-25	2006-06-20	Novo Nordisk A/S	Inhibition of beta cell degeneration
AU2001233622A1 (en)	2000-02-25	2001-09-03	Novo-Nordisk A/S	Inhibition of beta cell degeneration
ES2525041T3 (es) *	2000-03-31	2014-12-16	Royalty Pharma Collection Trust	Método para la mejora de la señalización de islotes en diabetes mellitus y para su prevención
US6890905B2 (en) *	2001-04-02	2005-05-10	Prosidion Limited	Methods for improving islet signaling in diabetes mellitus and for its prevention

2001
- 2001-04-02 ES ES08172906.3T patent/ES2525041T3/es not_active Expired - Lifetime
- 2001-04-02 CA CA002400226A patent/CA2400226C/en not_active Expired - Lifetime
- 2001-04-02 CN CN01807402A patent/CN1420797A/zh active Pending
- 2001-04-02 EP EP08172906.3A patent/EP2055302B1/en not_active Expired - Lifetime
- 2001-04-02 RU RU2002129014/14A patent/RU2261096C2/ru active
- 2001-04-02 HU HU0204459A patent/HU229042B1/hu unknown
- 2001-04-02 AT AT01927848T patent/ATE419036T1/de active
- 2001-04-02 CN CN200910208114A patent/CN101690815A/zh active Pending
- 2001-04-02 PT PT01927848T patent/PT1283735E/pt unknown
- 2001-04-02 AU AU2001254763A patent/AU2001254763A1/en not_active Abandoned
- 2001-04-02 EP EP10179515.1A patent/EP2266665B1/en not_active Expired - Lifetime
- 2001-04-02 PT PT81729063T patent/PT2055302E/pt unknown
- 2001-04-02 ES ES01927848T patent/ES2320630T5/es not_active Expired - Lifetime
- 2001-04-02 EP EP01927848A patent/EP1283735B2/en not_active Expired - Lifetime
- 2001-04-02 WO PCT/EP2001/003725 patent/WO2001072290A2/en not_active Ceased
- 2001-04-02 KR KR1020027013054A patent/KR20030019337A/ko not_active Ceased
- 2001-04-02 DK DK01927848.0T patent/DK1283735T4/da active
- 2001-04-02 IL IL15136801A patent/IL151368A0/xx active IP Right Grant
- 2001-04-02 US US09/824,622 patent/US6500804B2/en not_active Expired - Fee Related
- 2001-04-02 BR BR0109553-6A patent/BR0109553A/pt not_active Application Discontinuation
- 2001-04-02 PT PT101795151T patent/PT2266665T/pt unknown
- 2001-04-02 KR KR1020087014806A patent/KR20080067009A/ko not_active Ceased
- 2001-04-02 JP JP2001570251A patent/JP2003528135A/ja active Pending
- 2001-04-02 CZ CZ20023234A patent/CZ20023234A3/cs unknown
- 2001-04-02 DE DE60137216T patent/DE60137216D1/de not_active Expired - Lifetime
- 2001-04-02 ES ES10179515.1T patent/ES2582376T3/es not_active Expired - Lifetime
- 2001-04-02 DK DK08172906.3T patent/DK2055302T3/da active
2002
- 2002-07-16 US US10/196,038 patent/US20020198242A1/en not_active Abandoned
- 2002-07-22 US US10/200,870 patent/US20030008905A1/en not_active Abandoned
- 2002-08-13 ZA ZA200206460A patent/ZA200206460B/en unknown
- 2002-09-27 NO NO20024643A patent/NO20024643L/no unknown
2003
- 2003-10-01 US US10/676,832 patent/US20050222221A1/en not_active Abandoned
2004
- 2004-08-02 US US10/910,176 patent/US20050014703A1/en not_active Abandoned
2006
- 2006-06-01 AU AU2006202344A patent/AU2006202344B2/en not_active Expired
2009
- 2009-03-12 CY CY20091100280T patent/CY1108872T1/el unknown

Also Published As

Publication number	Publication date
ES2525041T3 (es)	2014-12-16
ZA200206460B (en)	2003-08-13
DK1283735T3 (da)	2009-04-06
DE60137216D1 (de)	2009-02-12
EP2055302A1 (en)	2009-05-06
ATE419036T1 (de)	2009-01-15
HK1130015A1 (en)	2009-12-18
EP2266665A1 (en)	2010-12-29
EP2266665B1 (en)	2016-05-11
AU2006202344B2 (en)	2009-01-08
US20030008905A1 (en)	2003-01-09
HUP0204459A2 (en)	2003-05-28
CY1108872T1 (el)	2014-07-02
BR0109553A (pt)	2003-06-03
WO2001072290A3 (en)	2002-03-14
PT1283735E (pt)	2009-03-19
AU2006202344A1 (en)	2006-06-22
CN1420797A (zh)	2003-05-28
PT2055302E (pt)	2014-12-03
RU2261096C2 (ru)	2005-09-27
HU229042B1 (en)	2013-07-29
ES2582376T3 (es)	2016-09-12
US20010051646A1 (en)	2001-12-13
EP1283735A2 (en)	2003-02-19
HK1051007A1 (en)	2003-07-18
AU2001254763A1 (en)	2001-10-08
KR20080067009A (ko)	2008-07-17
KR20030019337A (ko)	2003-03-06
US20050222221A1 (en)	2005-10-06
PT2266665T (pt)	2016-07-07
US20050014703A1 (en)	2005-01-20
NO20024643L (no)	2002-11-05
JP2003528135A (ja)	2003-09-24
EP1283735B1 (en)	2008-12-31
EP2055302B1 (en)	2014-09-10
ES2320630T3 (es)	2009-05-27
CA2400226C (en)	2007-01-02
US6500804B2 (en)	2002-12-31
DK2055302T3 (da)	2014-10-27
ES2320630T5 (es)	2013-03-12
IL151368A0 (en)	2003-04-10
HUP0204459A3 (en)	2006-01-30
CZ20023234A3 (cs)	2003-01-15
DK1283735T4 (da)	2013-02-04
EP1283735B2 (en)	2012-10-24
WO2001072290A2 (en)	2001-10-04
US20020198242A1 (en)	2002-12-26
CA2400226A1 (en)	2001-10-04
CN101690815A (zh)	2010-04-07

Publication	Publication Date	Title
NO20024643D0 (no)	2002-09-27	Fremgangsmåte for forbedring av öy-signalisering i diabetes mellitus og for forebygging derav
BR0111800A (pt)	2003-05-27	Combinações de inibidores de depeptidil peptidase iv e outros agentes antidiabéticos para o tratamento de diabete mellitus
CY1108769T1 (el)	2014-04-09	Αναστολεις της διπεπτιδυλικης πεπτιδασης iv για μειωση του ρυθμου της χρονιας αυξησης βαρους
NO20023473L (no)	2002-09-23	Sammensetninger for levering av en kortisol antagonist
PL373361A1 (en)	2005-08-22	Erythropoietin ameliorates chemotherapy-induced toxicity in vivo
NO20083276L (no)	2000-02-17	Behandling av diabetes med tiazolidindion og sulfonylurea
KR101921363B1 (ko)	2018-11-22	결합 조직 질환을 치료하기 위한 브로멜라인으로부터의 단백분해 추출물
BG104062A (en)	2000-11-30	Treatment of diabetes with thiazolidindion, stimulant of insulin secretion and alpha-glucosidase inhibitor
AP9901720A0 (en)	1999-12-31	Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitors.
CY1117624T1 (el)	2017-04-26	Μεθοδος για τη βελτιωση της σηματοδοτησης νησιδιων στον σακχαρωδη διαβητη και την προληψη
WO2007105218A3 (en)	2008-12-31	Composition and method for brain tumor therapy
IL162268A0 (en)	2005-11-20	Tempamine compositions and methods of use
MX2007012991A (es)	2008-03-13	Formas solidas cristalinas y amorfas de halofenato (-) y metodoss relacionados a las mismas.
CO5150158A1 (es)	2002-04-29	Tratamiento antidiabetico novedoso
MXPA04006269A (es)	2004-09-27	Composicion farmaceutica que comprende un inhibidor de alfa-glucosidasa y acido 4-oxobutanoico y uso de la misma para tratamiento de diabetes.
ATE359789T1 (de)	2007-05-15	Verwendung von 4-pyridylmethyl-phthalazin- derivaten zur herstellung eines medikaments zur behandlung von myelodysplastischen syndromen
ECSP982535A (es)	1999-04-13	Nuevo metodo de tratamiento (i)
ECSP982541A (es)	1999-02-11	Nuevo metodo de tratamiento ii
RU2002115215A (ru)	2003-12-20	Способ лечения тромбофлебита